### Q3FY23 Result Update | Chemicals | 14 February 2023

# **NOCIL Ltd.**

### Q3 below expectations, Near-term pains are visible

NOCIL reported a weaker show on all fronts during Q3FY23. Revenue de-grew by ~16% both YoY and QoQ because of lower volumes & lower realization. Domestic market volumes were impacted because of higher inventory & weak demand from replacement segment. Export volumes remained flattish on sequential basis. Despite revenue decline of 16% QoQ, EBITDA declined by 39.4% QoQ owing to higher employee and other expenses which impacted the EBITDA spreads in Q3FY23. We anticipate pickup in volumes from the coming quarters but increased competition from imports could be a near term concern which could impact its EBITDA spreads for the near term. Although, the long-term growth story remains positive for NOCIL, owing to tyre players expanding capacity which leads to increased usage of rubber chemicals, still competitive intensity is set to increase with competitors ramping up capacity (For instance. China Sunshine recently completed 30,000 TPA anti-oxidant capacity addition & planning another 20,000 TPA accelerator capacity addition by end of 2023) could spoil the party for NOCIL. Considering the demand pain in the domestic replacement market & poor product mix (generally value-added portfolio is ~25% of overall volumes majorly catering to exports market, current scenario of lower export sales leading to decline of value added portfolio & thereby, leading to poor product mix). Considering near-term pains, we downgrade stock to ACCUMULATE from earlier BUY rating.

### Operating margin contracted sequentially, weak demand led to lower performance

- The company's EBITDA or operating margin contracted by 151bps YoY & 439bps QoQ to 11.5% in Q3FY23. This is largely due lower gross margins and increased employee and other expenses.
- EBITDA spreads reported decline of 6.7% YoY & 34% QoQ to Rs 34.3 per kg in Q3FY23, which is lower than the average range of last 10 years, majorly led by lower volumes offtake and poor product mix. Considering the improved mix towards specialized/higher value added products and rising exports share over the last few years, we feel the current spreads (reported in Q3FY23) should improve over the next 2-3 years.
- Accordingly, we model in EBITDA spreads of Rs 48.6 & Rs 48.1 per kg for FY24E & FY25E respectively.
- Since, company works on a competitive pricing model, wherein increase/decrease in input cost would be passed on subject to similar approach adopted by competitors in the market. For the coming quarter, one of the major raw material viz. Aniline prices has witnessed steep decline in prices and will remain volatile due to which the company to adopt similar approach in their product basket.

### Sequentially volumes contracted steeply, gloomy demand outlook remains a pain in near term

- In Q3FY23, volume contracted by 20.7% YoY & 7.5% QoQ majorly because of lower volume offtake in the domestic market, though exports market remained flattish sequentially. However, uncertainty of demand in both domestic and exports market led by weakness in replacement segment and higher channel inventory of tyre players remains a big cause of concern. We anticipate demand weakness might continue along with increase in imports could spoil the party for NOCIL in the short term for the coming quarters.
- We expect the company expanded capacity of 55,000 TPA is likely to reach optimum utilization levels by FY24E & debottlenecking to support volume growth beyond FY24 for more than a year. On the back of this, we expect NOCIL to report volume CAGR growth of ~4.2% from FY22-25E.

### **Valuations**

- We feel that demand weakness in replacement segment could impact domestic tyre market along with slowing export market might remain an overhang in the near term.
- Considering pressure on spreads, we have cut down our earnings estimates by 20%-25% for coming years.
- We value the stock using EV/EBITDA multiple and arrive at target price of 223 per share (assigning ~11.5x EV/EBITDA to FY25E projections) which indicates upside of 5.0% from current level. Hence, we downgrade to ACCUMULATE rating from earlier BUY rating on the stock.

Y/E Mar (Rs mn)	Q3FY23	Q3FY22	YoY (%)	Q2FY23	QoQ (%)	Q3FY23E	Var(%)
Revenue	3,257	3,889	-16.2%	3,892	-16.3%	3,772	-13.6%
Operating cost	2,881	3,382	-14.8%	3,272	-11.9%		
EBITDA	376	508	-26.0%	620	-39.4%	538	-30.2%
EBITDA margin (%)	11.5%	13.0%	(151) bps	15.9%	(439) bps	14.3%	(273) bps
Depreciation	142	108	31.0%	140	1.6%		
Interest	3	3	10.7%	3	-8.8%		
Other Income	22	5	351.0%	9	157.0%		
Exceptional Items	0	0	NA	0	NA		
PBT	253	401	-36.9%	486	-47.9%		
Taxes paid	67	104	-35.4%	128	-47.9%		
Reported PAT	186	298	-37.5%	357	-47.9%	321	-41.9%



Rating: ACCUMULATE	Upside: 5%
Current Price: 212	Target Price: 223

#### | Earlier Recommendation

Previous Rating:	BUY
Previous Target Price:	273

#### | Market data

Bloomberg:	NOCIL: IN
52-week H/L (Rs):	295/191
Mcap (Rs bn/USD bn):	35.5/0.44
Shares outstanding (mn):	166.6
Free float:	56.1%
Daily vol. (3M Avg.):	2.3mn
Face Value (Rs):	10
Group:	NIFTY 500
Source: Bloomberg, SMIFS Research	

-

#### |Shareholding pattern (%)

	Dec-22	Sep-22	Jun-22	Mar-22
Promoter	33.8	33.8	33.8	33.8
FIIs	5.3	4.5	2.9	2.5
DIIs	4.8	5.1	4.9	4.3
Public/others	56.1	56.6	58.4	59.4
Source: BSE				

### |Price performance (%)\*

	1M	3M	12M	36M
NIFTY 50	-1.0	-3.2	2.3	46.0
NIFTY 500	-2.9	-4.8	0.1	48.8
NOCIL	-7.0	-8.3	-3.5	137

\*as on 13th Feb 2023; Source: AceEquity, SMIFS Research

Aditya Khetan

Sector Lead- Chemicals +91 9004126470

aditya.khetan@smifs.co.in

Awanish Chandra

Executive Director +91 8693822293

awanish.chandra@smifs.com

Y/E Mar (Rs mn)	Revenue	YoY (%)	EBITDA	EBITDA (%)	Adj PAT	YoY (%)	EPS	RoE (%)	RoCE (%)	P/E (x)	EV/EBITDA (x)
FY21	9,247	9.3	1,308	14.1	884	-32.3	5.3	7.2	7.2	23.8	15.2
FY22	15,713	69.9	2,862	18.2	1,761	99.2	10.6	12.9	12.9	22.5	13.8
FY23E	15,825	0.7	2,394	15.1	1,406	-20.1	8.4	9.5	9.5	27.2	15.6
FY24E	16,263	2.8	2,681	16.5	1,613	14.7	9.7	10.3	10.3	23.8	13.6
FY25E	16,780	3.2	2,905	17.3	1,771	9.8	10.6	10.6	10.6	21.6	12.2

Source: Company, SMIFS Research Estimates



# **Analyst Call Highlights**

- **Demand outlook:** The demand of rubber chemical in the exports market is weak considering the recent headwinds like inflationary pressure, geopolitical tensions & volatile oil prices. Also, domestic demand has started to weaken led by slowing replacement segment & higher inventory with tyre counterparts. Demand of rubber chemicals is expected to increase in the long term with subsequent pick up in auto, tyre sector and other allied sector which consumes rubber.
- Sales volume: The company reported volume decline of ~20.7% YoY & 7.5% QoQ in Q3FY23.
- Realization commentary: During the quarter realizations has declined by 9.3% QoQ. Decline in rubber chemical prices seems to be a pass on effect since raw material prices are also declining.
- Earlier, the management guided the expanded capacity would reach optimum utilization by September 2023, however citing the uncertain global enviournment management has dropped its guidance.
- Tyre sector outlook: The domestic OEM auto and tyre sector has witnessed robust performance and the long-term growth outlook is intact. Replacement demand which constitutes 60-70% of tyre sector has faced headwinds led by weak pickup in demand. Tyre players globally have lined up Rs550bn-600bn in creating additional capacities which bodes well for companies like NOCIL and other rubber chemical companies.
- Strategy going ahead: Management has clearly stated that they are focusing on improving market share on the back of increased volumes from the expanded capacity going ahead.
- Debottlenecking of capacities will be done in Dahej plant only for some product range which portray strong growth momentum. This capacity would be sufficient for another 1-1.5 years time frame to sustain volume growth momentum.



## **Valuation and Recommendations**

We feel that demand weakness in replacement segment could impact domestic tyre market along with slowing export market might remain an overhang in the near term.

We value the stock using EV/EBITDA multiple and arrive at target price of 223 per share (assigning ~11.5x EV/EBITDA to FY25E projections) which indicates upside of 5% from current level.

Hence, we downgrade to ACCUMULATE rating from earlier BUY rating on the stock.

Fig 1: 1-year forward P/E



Fig 2: 1-year forward EV/EBITDA



Source: AceEquity, SMIFS Research

Source: AceEquity, SMIFS Research



# **Quarterly financials, operating metrics and key performance indicators**

Fig 3: Quarterly Financials

Y/E March (Rs mn)	Q4FY21	Q1FY22	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23
Net Sales	3220	3445	3752	3889	4627	5089	3892	3257
Raw Materials	1798	1742	2231	2310	2312	2726	2057	1759
Employee Costs	172	217	195	194	194	240	213	214
Other Expenditure	727	752	823	878	1015	1090	1003	908
EBITDA	523	734	503	508	1105	1033	620	376
Depreciation	101	105	107	108	160	137	140	142
Interest	2	2	2	3	4	3	3	3
Other Income	23	11	14	5	11	4	9	22
РВТ	444	638	408	401	952	897	486	253
Tax	71	164	108	104	268	232	128	67
Tax rate (%)	16	26	26	26	28	26	26	26
Reported PAT	373	474	300	298	685	665	357	186
YoY Growth (%)								
Revenue	51.4	223.4	69.3	41.6	43.7	47.7	3.8	-16.2
EBITDA	43.0	820.1	58.8	33.2	111.2	40.7	23.3	-26.0
PAT	70.7	296.7	78.3	33.5	83.4	40.2	19.1	-37.5
QoQ Growth (%)								
Revenue	17.3	7.0	8.9	3.7	19.0	10.0	-23.5	-16.3
EBITDA	37.4	40.3	-31.5	0.9	117.8	-6.6	-40.0	-39.4
Adj. PAT	67.3	27.0	-36.7	-0.7	129.8	-2.9	-46.3	-47.9
Margin (%)								
EBITDA	16.3	21.3	13.4	13.0	23.9	20.3	15.9	11.5
PAT	11.6	13.8	8.0	7.7	14.8	13.1	9.2	5.7
Gross	44.2	49.4	40.5	40.6	50.0	46.4	47.2	46.0
Employee cost as % of sales	5.3	6.3	5.2	5.0	4.2	4.7	5.5	6.6
Other expenses as % of sales	22.6	21.8	21.9	22.6	21.9	21.4	25.8	27.9
Operational Metrics								
Volumes ( In KMT)	15.1	13.2	13.7	13.8	13.8	15.3	11.9	10.9
Realization per kg	213	261	274	282	335	333	328	298
Gross spreads per kg	94.2	129.0	111.0	114.4	167.8	154.5	154.8	136.9
EBITDA spreads per kg	34.7	55.6	36.7	36.8	80.1	67.5	52.3	34.3

Fig 4: Change in Estimates

	New Estimates			Old Estimates			(		
	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
Revenue	15825	16263	16780	17099	17764	18632	-7%	-8%	-10%
EBITDA	2394	2681	2905	3085	3340	3654	-22%	-20%	-21%
EBITDA Margin	15.1%	16.5%	17.3%	18.0%	18.8%	19.6%	(291) bps	(232) bps	(230) bps
PAT	1406	1613	1771	1921	2104	2329	-27%	-23%	-24%
EPS (Rs)	8	10	11	12	13	14	-27%	-23%	-24%

Source: Company, SMIFS Research Estimates



# **Financial Statements**

Income Statement					
YE March (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Revenues	9,247	15,713	15,825	16,263	16,780
Raw Materials	5,046	8,593	8,616	8,973	9,082
% of sales	54.6	54.7	54.4	55.2	54.1
Employee	701	808	887	993	1,072
% of sales	7.6	5.1	5.6	6.1	6.4
Other Expenses	2,192	3,450	3,928	3,616	3,721
% of sales	23.7	22.0	24.8	22.2	22.2
EBITDA	1,308	2,862	2,394	2,681	2,905
Other Income	147	39	43	48	52
Depreciation & Amortization	374	483	538	554	570
EBIT	1,081	2,417	1,899	2,175	2,387
Finance cost	10	11	11	9	9
Core PBT	924	2,367	1,845	2,118	2,326
PBT	1,071	2,406	1,888	2,166	2,378
Tax-Total	187	645	482	553	607
Tax Rate (%) - Total	17.5	26.8	25.5	25.5	25.5
PAT	884	1,761	1,406	1,613	1,771

Source:	Company	, SMIFS	Research	Estimates
---------	---------	---------	----------	-----------

Source: Company, SMIFS Research Estimates								
Key Ratios								
YE March	FY21	FY22	FY23E	FY24E	FY25E			
Growth Ratio (%)								
Revenue	9.3	69.9	0.7	2.8	3.2			
EBITDA	-26.6	118.8	-16.3	12.0	8.4			
PAT	-32.3	99.2	-20.1	14.7	9.8			
Margin Ratios (%)								
Gross Profit	45.4	45.3	45.6	44.8	45.9			
EBITDA	14.1	18.2	15.1	16.5	17.3			
EBIT	11.7	15.4	12.0	13.4	14.2			
Core PBT	10.0	15.1	11.7	13.0	13.9			
PAT	9.6	11.2	8.9	9.9	10.6			
Return Ratios (%)								
ROE	7.2	12.9	9.5	10.3	10.6			
ROCE	7.2	12.9	9.5	10.3	10.6			
Turnover Ratios (days)								
Gross block turn ratio (x)	0.8	1.3	1.2	1.2	1.8			
Adj OCF / PAT (%)	104.7	-17.8	183.0	120.1	126.3			
Inventory	120	141	140	140	140			
Debtors	122	104	90	90	90			
Creditors	123	91	90	85	85			
Cash conversion cycle	119	154	140	145	145			
Solvency Ratio (x)								
Debt-equity	0.0	0.0	0.0	0.0	0.0			
Net debt/equity	-0.1	0.0	-0.1	-0.1	-0.2			
Gross debt/EBITDA	0.0	0.0	0.0	0.0	0.0			
Current Ratio	16.2	20.3	19.0	20.0	21.6			
Interest coverage ratio	111	222	173	242	265			
Dividend								
DPS	2.0	3.0	3.6	4.0	4.4			
Dividend yield (%)	1.6	1.3	1.6	1.7	1.9			
Dividend payout (%)	37.7	28.4	42.6	40.9	41.0			
Per share (Rs)								
Basic EPS (reported)	5.3	10.6	8.4	9.7	10.6			
Adjusted EPS	5.3	10.6	8.4	9.7	10.6			
CEPS	7.6	13.5	11.7	13.0	14.1			
BVPS	77.1	86.8	91.6	97.3	103.6			
Valuation (x)								
Adj P/E	23.8	22.5	27.2	23.8	21.6			
P/BV	1.6	2.7	2.5	2.4	2.2			
EV/EBITDA	15.2	13.8	15.6	13.6	12.2			
EV / Sales	2.1	2.5	2.4	2.2	2.1			
Adj Mcap / Core PBT	21.4	16.6	20.2	17.2	15.2			
Adj Mcap / Adj OCF	21.4	-125.5	14.5	18.8	15.8			
Cauraci Campanii CMIFC I	Docooreh Fe	timantas						

Source: Company, SMIFS Research Estimates

Balance Sheet							
YE March (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E		
Source of funds							
Capital	1,662	1,666	1,666	1,666	1,666		
Reserves & Surplus	11,185	12,786	13,593	14,546	15,592		
Shareholders' Fund	12,847	14,452	15,259	16,212	17,258		
Total Debt	56	55	47	41	37		
Other Liabilities	1,156	1,232	1,255	1,306	1,357		
Total Liabilities	14,060	15,739	16,561	17,559	18,652		
Application of funds							
Gross Block	11,830	12,209	13,567	13,975	14,385		
Net Block	9,172	9,090	9,902	9,748	9,578		
Capital WIP	141	84	138	114	102		
Investments	689	539	386	398	400		
Other Non-Current Assets	352	329	334	351	369		
Inventories	1,657	3,327	3,305	3,442	3,484		
Sundry Debtors	3,086	4,498	3,902	4,010	4,138		
Cash and bank balances	804	160	874	1,758	2,874		
Other current assets	246	278	293	312	332		
Total Current Assets	5,792	8,263	8,374	9,522	10,828		
Sundry Creditors	1,701	2,151	2,124	2,090	2,115		
Other current liabilities	385	415	449	484	511		
Total Current Liabilities	2,086	2,566	2,573	2,573	2,626		
Net Current Assets	3,706	5,697	5,801	6,949	8,202		
Total Assets	14,060	15,739	16,561	17,559	18,652		
Source: Company, SMIFS Research Estimates							

Cash Flow					
YE March (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Operating profit before WC changes	1,321	2,855	2,437	2,728	2,957
Changes in working capital	-382	-2,560	630	-230	-104
Tax Paid	-4	-597	-482	-553	-607
Cash flow from operating activities	936	-302	2,585	1,946	2,246
Adj. OCF	926	-313	2,574	1,937	2,237
Capital expenditure	-1,363	-1,792	-1,405	-376	-389
Adj. FCF	-437	-2,105	1,169	1,561	1,848
Cash flow from investing activities	-621	312	-1,252	-387	-391
Debt	0	0	-8	-6	-4
Dividend	-7	-332	-600	-660	-726
Interest and lease	-4	-6	-11	-9	-9
Cash flow from financing activities	3	-336	-619	-675	-739
Net change in cash	317	-327	714	883	1,116

Source: Company, SMIFS Research Estimates



### **Disclaimer**

### **Analyst Certification:**

We /I, the above-mentioned Research Analyst(s) of SMIFS Limited (in short "SMIFS / the Company"), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

### **Terms & Conditions and Other Disclosures:**

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising



out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independednt views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.



SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at <a href="www.nseindia.com">www.nseindia.com</a> and/or <a href="www.nseindia.com">www.nseindi

SMIFS submit's that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.



### **Specific Disclosures**

- 1. SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2. SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- 3. SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- 4. SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- 5. Research Analyst has not served as director/officer/employee in the subject company
- 6. SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- 7. SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8. SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- 9. SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- 10. SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: NO

### **Key to SMIFS Investment Rankings**

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return <-5%

### Contact us:

SMIFS Limited. (https://www.smifs.com/)

### **Compliance Officer:**

### Sudipto Datta,

5F Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 / +91 33 6634 5401

Email Id.: compliance@smifs.com

### **Mumbai Office:**

206/207, Trade Centre, Bandra Kurla Complex (BKC), Bandra East, Mumbai – 400051, India

Contact No.: (D) +91 22 4200 5508, (B) +91 22 4200 5500

Email Id: institutional.equities@smifs.com

### **Kolkata Office:**

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India. Contact No.: (D) +91 33 6634 5408, (B) +91 33 4011 5400

Email Id: smifs.institutional@smifs.com